Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. comparison with anti-proliferative activity by RIL1-β, RTNF-α, RIFN-γ, RIl4 and their combinations

1990 ◽  
Vol 45 (2) ◽  
pp. 334-341 ◽  
Author(s):  
Roberta Mortarini ◽  
Filiberto Belli ◽  
Giorgio Parmiani ◽  
Andrea Anichini
Keyword(s):  
Proliferative Activity ◽  
Class Ii ◽  
Melanoma Cells ◽  
Hla Class Ii ◽  
Tumor Associated Antigen ◽  
Antigen Profile

HLA Class II Antigens on Melanoma Cells

1990 ◽  
pp. 197-211 ◽  
Author(s):  
G. Parmiani ◽  
A. Anichini ◽  
C. Castelli ◽  
G. Fossati
Keyword(s):  
Class Ii ◽  
Melanoma Cells ◽  
Hla Class Ii ◽  
Class Ii Antigens

scholarly journals Decreased Expression of HLA Class II Antigens on Human Uveal Melanoma Cells After In Vivo X-ray Irradiation

1988 ◽  
Vol 105 (1) ◽  
pp. 78-86 ◽  
Author(s):  
Martine J. Jager ◽  
Jeroen P. van der Pol ◽  
Didi de Wolff-Rouendaal ◽  
Paul T.V.M. de Jong ◽  
Dirk J. Ruiter
Keyword(s):  
Uveal Melanoma ◽  
Class Ii ◽  
Melanoma Cells ◽  
Hla Class Ii ◽  
X Ray ◽  
Class Ii Antigens

scholarly journals HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes

1995 ◽  
Vol 25 (10) ◽  
pp. 2732-2736 ◽  
Author(s):  
Eric Le Dréan ◽  
Nadine Gervois ◽  
Elisabeth Diez ◽  
Gilbert Semana ◽  
Brigitte Dreno ◽  
...  
Keyword(s):  
Class Ii ◽  
Melanoma Cells ◽  
Human Melanoma ◽  
Hla Class Ii ◽  
Human Melanoma Cells ◽  
Infiltrating Lymphocytes

scholarly journals Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules

1997 ◽  
Vol 71 (4) ◽  
pp. 630-637 ◽  
Author(s):  
Feng Yun Yue ◽  
Reinhard Dummer ◽  
Ralf Geertsen ◽  
Günther Hofbauer ◽  
Elisabeth Laine ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hla Class I ◽  
Class Ii ◽  
Interleukin 10 ◽  
Melanoma Cells ◽  
Human Melanoma ◽  
Hla Class Ii ◽  
Class I ◽  
Human Melanoma Cells

CD4 + T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro

2000 ◽  
Vol 48 (11) ◽  
pp. 621-626 ◽  
Author(s):  
Mary S. Brady ◽  
Fei Lee ◽  
H. Petrie ◽  
David D. Eckels ◽  
Janet S. Lee
Keyword(s):  
T Cells ◽  
Cd4 T Cells ◽  
Class Ii ◽  
Melanoma Cells ◽  
Hla Class Ii ◽  
Class Ii Antigen

scholarly journals Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1

2011 ◽  
Vol 271 (2) ◽  
pp. 392-400 ◽  
Author(s):  
Dan Zhao ◽  
Shereen Amria ◽  
Azim Hossain ◽  
Kumaran Sundaram ◽  
Peter Komlosi ◽  
...  
Keyword(s):  
T Cell ◽  
Class Ii ◽  
Melanoma Cells ◽  
Human Melanoma ◽  
Hla Class Ii ◽  
Cd4 T Cell ◽  
Cell Recognition ◽  
Bryostatin 1 ◽  
T Cell Recognition ◽  
Human Melanoma Cells

scholarly journals Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma

2009 ◽  
Vol 2009 ◽  
pp. 1-8 ◽  
Author(s):  
Duncan L. Norton ◽  
Azizul Haque
Keyword(s):  
T Cell ◽  
Metastatic Melanoma ◽  
Antigen Processing ◽  
Current Knowledge ◽  
Class Ii ◽  
Melanoma Cells ◽  
Current Treatment ◽  
Hla Class Ii ◽  
Cell Vaccine

Metastatic melanoma is one of the deadliest of skin cancers and is increasing in incidence. Since current treatment regimens are ineffective at controlling and/or curing the disease, novel approaches, such as immunotherapy, for treating this malignant disease are being explored. In this review, we discuss potential melanoma antigens (Ags) and their role in utilizing the HLA class II pathway to elicit tumor Ag-specificCD4+T cell responses in order to effectively induce long-lastingCD8+antitumor memory. We also discuss the role of endolysosomal cathepsins and Gamma-Interferon-inducible Lysosomal Thiol reductase (GILT) in Ag processing and presentation, and at enhancingCD4+T cell recognition of melanoma cells. This review also summarizes our current knowledge on GILT and highlights a novel mechanism of GILT-mediated immune responses against melanoma cells. At the end, we propose a strategy employing GILT in the development of a potential whole cell vaccine for combating metastatic melanoma.

Sign in / Sign up

Export Citation Format

Share Document